Xuanzhu Biopharmaceutical Co., Ltd.
軒竹生物科技股份有限公司
- Listing
- HKEX 02575
Clinical-stage assets
| Asset | Phase / approval scope | Indication | Source date |
|---|---|---|---|
| Bireociclib | Approved in China | HR-positive / HER2-negative advanced or metastatic breast cancer | 2026-04-09 |
| Dirozalkib | Approved in China | ALK-positive locally advanced or metastatic non-small cell lung cancer | 2026-04-09 |
Licensing announcements since 2025
| Date | Counterparty | Asset / platform | Upfront | Near-term | Potential total | Stage at announcement |
|---|---|---|---|---|---|---|
| 2026-04-09 | Boston Oncology CGT Holding Co. Limited | Bireociclib; Dirozalkib | Approved in China; licensed territories subject to local approval |